1027617-67-9

Basic information

• Product Name: 2,5,6,7-TETRAHYDRO-2-METHYL-4H-INDAZOL-4-ONE
• Synonyms: 2,5,6,7-TETRAHYDRO-2-METHYL-4H-INDAZOL-4-ONE;2-methyl-6,7-dihydro-5H-indazol-4-one
• CAS NO: 1027617-67-9
• Molecular Formula: C8H10N2O
• Molecular Weight: 150.1778
• Mol File: 1027617-67-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,5,6,7-TETRAHYDRO-2-METHYL-4H-INDAZOL-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5,6,7-TETRAHYDRO-2-METHYL-4H-INDAZOL-4-ONE(1027617-67-9)
• EPA Substance Registry System: 2,5,6,7-TETRAHYDRO-2-METHYL-4H-INDAZOL-4-ONE(1027617-67-9)

Safety Data

• Hazardous Substances Data: 1027617-67-9(Hazardous Substances Data)

Usage

General Description

2,5,6,7-Tetrahydro-2-methyl-4h-indazol-4-one is a chemical compound with the molecular formula C9H10N2O. It is a heterocyclic compound with a fused indazole ring system. 2,5,6,7-Tetrahydro-2-methyl-4h-indazol-4-one has potential applications in the pharmaceutical industry, particularly in the development of new drugs and therapeutic agents. Its structure and properties make it a promising candidate for further research and development in the field of medicinal chemistry. As a result, it is of interest to scientists and researchers seeking to explore its potential pharmacological activities and biological effects.

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 499206-33-6 2,5,6,7-tetrahydro-4H-indazol-4-one 
• 74-88-4 methyl iodide 
• 504-02-9 1,3-cylohexanedione 
• 912259-10-0 1⁽²⁾,5,6,7-tetrahydro-4H-indazole-4-one 
• 85302-07-4 2-(dimethylaminomethylene)cyclohexane-1,3-dione 
• 60-34-4 methylhydrazine 

Relevant articles and documents

Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif

A series of compounds were designed and synthesized based on the compound 11i bearing phenylpyrazole scaffold with histone deacetylase 6 (HDAC6) inhibitory activity. Most of the compounds showed considerable inhibitory activity against HDAC6 and compound

NEW AMINOPYRAZOLOQUINAZOLINES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferatio

An expedient synthesis of regioisomeric pyrazole-fused cycloalkanones

Described herein is a novel one-pot procedure for the synthesis of pyrazoles through the in situ generation of a monohydrazone of cyclic 1,3-diones and subsequent cyclization with N,N-dimethylformamide dimethyl acetal. This route provides pyrazoles that have limited accessibility by other methods. Georg Thieme Verlag Stuttgart.